was taken to the woodshed Thursday after the company said a trial of its lead product candidate, a hay fever treatment, fell short of the study's main goal. Shares of Rigel were plunging $13.79 ...

Rigel Pharmaceuticals Annual EPS Estimates (Seeking Alpha) As for the annual EPS, we can see that the Street has Rigel’s earnings rising through 2030, going from -0.38 for 2024 to 2.18 for 2030.

This article is based on a press release statement from Rigel Pharmaceuticals (NASDAQ:RIGL), Inc. The company maintains a healthy financial position with a current ratio of 1.96 and operates with ...

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today provided a business update including preliminary total ...